VenatoRx Receives $9.4 Million from CARB-X to Develop a New Class of Antibiotic to Combat Multi-Drug Resistant Bacteria

By WebmasterJuly 27, 2017November 1st, 2024No Comments

VenatoRx Receives $9.4 Million from CARB-X to Develop a New Class of Antibiotic to Combat Multi-Drug Resistant Bacteria

Previous PostBioAdvance investments topped $3M in fiscal 2017
Next PostVenatoRx Raises $42 Million Series B: Versant, Abingworth, Foresite Back Industry-Leading Antibiotics Developer